Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

infirst HEALTHCARE to Commercialise Novel Consumer Healthcare Drugs



     infirst HEALTHCARE to Commercialise Novel Consumer Healthcare Drugs

  PR Newswire

  LONDON, March 25, 2013

LONDON, March 25, 2013 /PRNewswire/ --

£25 Million Fundraising for Fast-to-Market Medicines

infirst HEALTHCARE, the consumer healthcare company commercialising unique,
fast-to-market consumer medicines, today announces it has successfully raised
£25 million of new funds. The funding, from Invesco Asset Management managed
funds, will be used for the launch of the company's medicines into the US$20
billion cough & cold and pain consumer healthcare markets where there has been
little innovation for decades.

The company's fast-to-market portfolio utilizes infirst ' s intellectual
property which centres on improving the profile of safe and well-established
drugs. The first products to be launched will be in the cough & cold and pain
indications. These represent the most prevalent symptomatic health conditions
at the primary care level and the two largest segments of the global OTC
market.

infirst HEALTHCARE is led by Manfred Scheske, who was President of
GlaxoSmithKline's US$3 billion European Consumer Healthcare business until
2010, overseeing and launching some of the largest consumer healthcare brands
in the industry. infirst ' s management team also includes Andrew Waters as
Chief Financial Officer, a PwC qualified accountant who held senior finance
roles with GlaxoSmithKline Consumer Healthcare & Pharma for 16 years.
Infirst's Board will be chaired by former Rothschild investment banker, Dr
Lynn Drummond, who has a strong track record in the healthcare sector bringing
over 20 years of management and advisory experience. Also on infirst ' s Board
will be Gregory Stoloff (CEO and founder of SEEK Group, from which infirst
HEALTHCARE has been spun out) and Kimbell Duncan (who has over 25 years
experience as investment banker and investor).

Infirst has developed a strong portfolio of pipeline products. Its strategic
focus - ' Known drugs   -   made better ' - unlocks opportunities which permit
rapid product development, swift pathways to regulatory approval and IP
protection.

Infirst will launch its first product, a cocoa-flavoured cough liquid, in
Europe. The company is also developing a non-narcotic/non-opioid cough
treatment which is in a Phase III clinical study, targeted for a 2015 market
launch. The North American rights to infirst ' s cough related IP have been
out-licensed to NASDAQ listed US company Pernix Therapeutics Holdings, Inc. 
infirst is also developing an ibuprofen-based product for the treatment of
inflammatory pain, to which it has the global rights.

Commenting on today's announcement, Manfred Scheske, CEO of infirst
HEALTHCARE, said:

"Cough & cold and pain are the largest and most prevalent conditions in the
consumer health sector and represent an enormous opportunity for infirst to
bring innovation and efficacy to a market which has seen very few new products
and only marginal innovation for decades. We are delighted that Invesco has
become a major shareholder in our company and we look forward to delivering
value for all of our shareholders in the coming years."

About   infirst     HEALTHCARE

infirst HEALTHCARE is a new consumer healthcare company focused on improving
well established  drugs with IP protected solutions for the OTC/Primary care
markets which can be launched within 12-36 months. infirst is a spin-out from
SEEK, a UK privately-owned drug discovery group which uses its intellectual
property to create breakthrough medicines addressing major diseases, bringing
radical improvements to human health.

infirst is led by CEO, Manfred Scheske, who  was previously President of GSK's
US$3 billion European Consumer Healthcare business (including brands such as
alli, Aquafresh, Beechams, Corsodyl, Lucozade, Niquitin, Panadol. Piriton,
Poligrip, Ribena, Sensodyne, Solpadeine, Zantac and Zovirax ) from 2004 to
2010 and also spent six years as President of GSK's Consumer Healthcare
business in North America.

About SEEK

Founded in 2004, SEEK (previously known as PepTcell) is privately-owned and
funded, with headquarters in London, UK. Using a pioneering scientific and
commercially-driven approach, SEEK aims to create breakthrough medicines which
address major diseases in order to radically improve human health. SEEK's
strategy is to take promising molecules through the challenging stages of
discovery to late-stage human proof-of-principle and then to seek partners to
take the molecules through the final stages of development and ultimately
commercialisation. Additional information about SEEK is available on the
Company's website located at http://www.seekacure.com

About Invesco Perpetual

Invesco Perpetual is the trading name of Invesco Asset Management Limited and
one of the largest independent investment managers in the UK. Their investment
approach is rooted in the view that there are no short cuts to long-term
investment success. Their fund managers have a wealth of expertise and are
focused on achieving the objectives of the funds they manage. More information
can be found on their web site at   http://www.invescoperpetual.co.uk

About Cough

More common than heartburn and severe headaches, cough imposes a great burden
on the sufferer, their families, and society.  Afflicting over 800 million
worldwide, with an estimated 12% of the general population (7.5 million in the
UK), experiencing the symptom on a regular basis. Most current cough remedies
have old, grandfathered licenses and many are of narcotic/ opioid nature.

For more information please contact: Manfred Scheske, CEO, infirst HEALTHCARE
:  Tel +44(0)20-7153-6570 M:CommunicationsMary Clark / Amber Bielecka / Hollie
Vile - Tel +44(0)20-7920-2330 infirsthealthcare@mcomgroup.com Peel Hunt LLP
(Financial Adviser to infirst HEALTHCARE)  James Steel / Vijay Barathan:  Tel
+44(0)20-7418-8900
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement